65162-411 : Levomilnacipran 20 mg Oral Capsule, Extended Release

Labeler: Amneal Pharmaceuticals LLC
Product Type: Human Prescription Drug
Drug Name:  Levomilnacipran
Dosage Form: Oral Capsule, Extended Release
Application #: ANDA210790
Rev. Date: 


Markings: AN;411
Shapes:  Capsule
Colors:  Yellow
Size (mm): 14
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

NDC Package Codes:

  • 65162-411-03: 30 CAPSULE, EXTENDED RELEASE IN 1 BOTTLE (65162‑411‑03)

Active Ingredients:

  • Levomilnacipran Hydrochloride

Dosage Strength:

  • 20 mg

Inactive Ingredients:

  • Alcohol
  • Ammonia
  • Butyl Alcohol
  • Ethylcellulose (20 Mpa.s)
  • Ferric Oxide Yellow
  • Ferrosoferric Oxide
  • Hypromelloses
  • Isopropyl Alcohol
  • Potassium Hydroxide
  • Povidone
  • Propylene Glycol
  • Shellac
  • Starch, Corn
  • Sucrose
  • Talc
  • Titanium Dioxide
  • Triethyl Citrate
  • Water /

Pharmaceutical Classes:

  • Norepinephrine Uptake Inhibitors [MoA]
  • Serotonin Uptake Inhibitors [MoA]
  • Serotonin and Norepinephrine Reuptake Inhibitor [EPC]

Related Products:

Based on records with the same trade name.
  • 65162-437 Levomilnacipran 80 mg Oral Capsule, Extended Release by Amneal Pharmaceuticals LLC
  • 65162-455 Levomilnacipran 120 mg Oral Capsule, Extended Release by Amneal Pharmaceuticals LLC
  • 65162-960 Levomilnacipran 40 mg Oral Capsule, Extended Release by Amneal Pharmaceuticals LLC


Scan the QR code below to easily reference this data in the future:

NDC 65162-411 QR Code

< Prev: 65162-379Next: 65162-414 >

Note: The MedsChat® NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.